One-carbon Therapeutics AB

One carbon therapeutics is developing innovative therapeutics for oncology indications with high unmet medical needs founded on state-of-the-art science from Karolinska Institute. We were co-founded in 2020 by the Helleday Laboratory. We have over 20 years of experience in DNA damage response biology and previous success of discovering the synthetic lethal concept for treating BRCA mutated cancer with PARP inhibitors. Our lead clinical candidate TH9619 is a first-in-class, small-molecule MTHFD1/2 inhibitor that shows remarkable efficiency in multiple cancer models. We hold a strong patent for our compound portfolio and are currently developing TH9619 for biomarker-selected solid and haematological cancers. TH9619 has entered the NDA submission preparation phase, and we aim to initiate the phase 1 trial in 2024. We are interested in talking to potential partners for further clinical and commercial development.